



6A

Response rate by oncogene amplification (cn>5) and TSG homozygous deletion (cn=0) status:




6B




6C

Cohort: UROTHELIAL-MARIATHASAN_NATURE_2018



6D


Urothelial immune checkpoint inhibitor treated patients from MSK-IMPACT cohort:



CCND1 no amp	202	89	37	15	5
CCND1 amp	12	2	1	0	0

6E


Urothelial non-immune checkpoint inhibitor treated patients from MSK-IMPACT cohort:



CCND1 no amp	151	120	69	21	2
CCND1 amp	8	4	3	0	0

6F


Pancan immune checkpoint inhibitor treated patients from MSK-IMPACT cohort:



CCND1 no amp	1619	426	84	15	2
CCND1 amp	42	3	0	0	0

6G

Pancan non-immune checkpoint inhibitor treated patients from MSK-IMPACT cohort:



CCND1 no amp	5190	3720	1607	439	34	0
CCND1 amp	86	54	24	4	1	0